Later, imatinib was also found to block the kinase activity of FIP1L1-PDGFRA, the major driver of oncogenesis in chronic eosinophilic leukemia (CEL) and in a subset of related myeloid malignancies [107,108]. This evidence concerns the gene PDGFRA and Chronic Eosinophilic Leukemia, Not Otherwise Specified.